← Leaderboards
David Tsai Ting
Massachusetts General Hospital
$4,336,400
Attributed
$9,742,406
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2019–24$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,742,406 · 3
By mechanism
R01$6,514,830 · 2
U01$3,227,576 · 1
Top collaborators
- Benjamin Greenbaum13 shared
- Nabeel Bardeesy7 shared
- Raul Mostoslavsky7 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Benjamin Greenbaum$3,266,793
- Raul Mostoslavsky$11,553,356
- Jose M Teixeira$9,923,155
- Kamila Naxerova$7,833,583
- Nabeel Bardeesy$18,920,034
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroTranscriptome SequencingCellsIn VivoMalignant NeoplasmsGenetic TranscriptionSamplingLinkTumorGenesMouse ModelNormal Tissue MorphologyColorectal CancerBiological ModelsVirusRepetitive SequenceImmuneImmune ResponseResponseEpigenetic ProcessGenetic ManipulationDesignColon CarcinomaImmunohistochemistry
Grant awards (20)
A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor Immunity$617,031
U01 · FY2024 · CA
A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor Immunity$636,517
U01 · FY2023 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer$565,924
R01 · FY2023 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$562,581
R01 · FY2023 · CA
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$233,789
R01 · FY2023 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer$134,995
R01 · FY2023 · CA · contact PI
A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor Immunity$636,517
U01 · FY2022 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer$565,924
R01 · FY2022 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$562,581
R01 · FY2022 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer$134,995
R01 · FY2022 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$127,680
R01 · FY2022 · CA
A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor Immunity$649,506
U01 · FY2021 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer$577,473
R01 · FY2021 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$574,063
R01 · FY2021 · CA
Understanding the Relationship of Repeat Expression and Metastasis$137,750
R01 · FY2021 · CA · contact PI
A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor Immunity$688,005
U01 · FY2020 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer$577,473
R01 · FY2020 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$574,063
R01 · FY2020 · CA
Reverse transcriptase inhibitor effects on the mobilome of colon cancer$611,476
R01 · FY2019 · CA · contact PI
Mechanistic Understanding for the Role of Lin28b in Pancreatic Cancer Progression$574,063
R01 · FY2019 · CA